DE-ROCKET.CHAT
22.7.2021 14:02:09 CEST | Business Wire | Press release
Rocket.Chat , the leading open-source communication hub, is announcing the release of Catalyst , its new partner program that consolidates all the assets needed to accelerate growth of new and existing partners across the globe.
“Since the beginning we have been working in close collaboration with service and technology providers to deliver increased value to our customers, which naturally led us to clearly understand the key aspects needed to support our partners’ growth throughout their journey and ultimately leverage their ROI through our partnership. Rocket.Chat’s Catalyst materializes these learnings into a journey-based program that will support companies of all sizes that target the same market and want to establish a results-driven, long-lasting relationship with Rocket.Chat,” said Julio Azzini, Global Head of Partnerships at Rocket.Chat.
The pandemic forced businesses around the globe to abruptly adopt the remote work environment, on a never-before-seen scale. This presented a unique opportunity for Rocket.Chat, helping to boost the company’s hyper growth - a trend that is set to continue as evidence mounts that the remote work momentum will not fade away for the foreseeable future. As an open-source business, Rocket.Chat benefits from a strong global footprint across different sectors that, combined with its recent Series A funding round , will accelerate growth and create opportunities for both Rocket.Chat and its partner ecosystem.
“The investment we made to revamp our existing (partner) program reinforces our commitment to our partners and ultimately, to our customers, to better serve them at a local level and on a global scale. Our partner ecosystem plays a crucial role in our go-to-market strategy,” shared Gabriel Engel, co-founder and CEO of Rocket.Chat. “Partners act as our service arm because they are the ones who are implementing strategic projects, scaling our apps and setting up the integrations that enable our customers to personalize and make the most of their Rocket.Chat experience.”
The new program encompasses a self-paced, scalable onboarding process that enables all key roles within a partner organization to sell and deliver projects through the Rocket.Chat partner portal. The robust capabilities of the program increase collaboration between internal teams and external providers to better manage the partner experience and overall journey while working within Rocket.Chat.
“We decided to implement the same training that we provide to our internal team to our partners. We see our partner relationships as a critical part of our company, rather than just a go-to-market channel. On top of all improvements made we have hired a very talented and competent group of professionals, now outfitted with the assets they need to ensure that we are taking our partner program -- and ultimately our partnerships -- to the next level,” added Azzini.
The new partner program operates across three tiers that are organized based on the overall capabilities and contributions of partners across all types of business models. For more information, please visit: www.Rocket.Chat/partners
About Rocket.Chat
Rocket.Chat is used by Audi, Alfa-Bank, Caixa, Daimler, HTC, Intel, Lockheed Martin, Nationwide Insurance, and other enterprises worldwide to control their communication, manage their data, and have their own collaboration platform to improve team productivity. Rocket.Chat users can switch between team chat and video or audio calls with screen sharing for more efficient teamwork. The platform’s open-source foundation empowers enterprises with complete access to the source code so that they can fully customize, extend or add new functionality to meet their unique requirements. Rocket.Chat is now installed on more than 700,000 servers, counts over 12 million users worldwide, and has an active, passionate community of over 800 developer-contributors who help Rocket.Chat’s core team of developers to constantly improve the product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005172/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom